FrancophonIA/ELRC3.0 huggingface dataset:
English: It can be used to treat aspergillosis in cockatoos, parrots, parakeets, budgerigars, falcons, hawks, owls and swans, and also to treat candidiasis in cockatoos, parrots, parakeets and budgerigars.
Estonian: Seda kasutatakse aspergilloosi raviks kakaduudel, papagoidel, väikestel pikasabalistel papagoidel, viirpapagoidel, pistrikel, haugastel, kakkudel ja luikedel ning kandidoosi raviks kakaduudel, papagoidel, väikestel pikasabalistel papagoidel ja viirpapagoidel.
English: Fungitraxx must not be used in birds intended for human consumption.
Estonian: Fungitraxxi ei tohi kasutada inimtoiduks tarvitatavatel lindudel.
English: The benefit-risk balance may be found in the scientific discussion module of this EPAR.
Estonian: Ravimi kasulikkuse ja riski suhe on Euroopa avaliku hindamisaruande teadusliku arutelu jaotises.
English: Fungitraxx is used to treat ornamental birds with two types of fungal infections of the respiratory tract (aspergillosis and candidiasis).
Estonian: Fungitraxxi kasutatakse ilulindudel kahte tüüpi hingamisteede infektsioonide (aspergilloos ja kandidoos) raviks.
English: Why has Fungitraxx been approved?
Estonian: Miks Fungitraxx heaks kiideti?
English: What is Fungitraxx?
Estonian: Mis on Fungitraxx?
English: Vomiting, loss of appetite and weight loss are common in treated birds (seen in up to 1 in 10 birds).
Estonian: Ravitud lindudel võib sageli (kuni 1 linnul 10st) esineda oksendamist, söögiisu vähenemist ja kehakaalu langust.
English: What is the risk associated with Fungitraxx?
Estonian: Mis riskid Fungitraxxiga kaasnevad?
English: It works by blocking the production of a compound in the fungus called ergosterol which is an important part of fungal cell membranes.
Estonian: Fungitraxx blokeerib seenerakkudes seene rakumembraani tähtsa komponendi ergosterooli tootmise.
English: How does Fungitraxx work?
Estonian: Kuidas Fungitraxx toimib?
English: Hands and exposed skin should be washed after using Fungitraxx.
Estonian: Pärast Fungitraxxi kasutamist tuleb pesta käed ja ravimiga kokku puutunud nahapind.
English: Itraconazole is an antifungal medicine.
Estonian: Fungitraxx on seenevastane ravim.
English: Haemoglobin levels should be monitored every two weeks until they are stable, and then periodically.
Estonian: Hemoglobiini sisaldust peab jälgima iga kahe nädala tagant kuni see on stabiilne ja seejärel regulaarselt.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Mircera on 20 July 2007.
Estonian: Euroopa Komisjon andis Mircera müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 20. juulil
English: The full EPAR for Mircera can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Mircera kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: It is also cleared from the body less quickly.
Estonian: Toimeaine väljub organismist ka aeglasemalt.
English: Mircera is intended for long-term use.
Estonian: Mircera on ette nähtud pikaajaliseks kasutamiseks.
English: The effectiveness of the two treatment options was compared over 36 weeks.
Estonian: 36 nädala kestel võrreldi nende kahe raviviisi efektiivsust.
English: The most common side effect with Mircera (seen in between 1 and 10 patients in 100) is hypertension (high blood pressure).
Estonian: Mircera kõige sagedam kõrvalnäht (esinenud 1-10 patsiendil 100st) on hüpertensioon (kõrge vererõhk).
English: As a result, Mircera can be given less often than natural erythropoietin.
Estonian: Seetõttu võib Mircerat manustada harvemini kui looduslikku erütropoetiini.
English: The Committee decided that Mircera's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Komitee otsustas, et Mircera kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
English: Mircera can be injected under the skin or into a vein.
Estonian: Mircerat võib süstida naha alla või veeni.
English: However, the way it interacts with the receptor is slightly different from natural erythropoietin, which gives it a longer effect.
Estonian: Toimeaine mõjutab retseptorit siiski veidi teistmoodi kui looduslik erütropoetiin ja toime on seetõttu pikem.
English: Most patients also received iron to prevent deficiency (low iron levels) during the studies.
Estonian: Enamik patsiente said uuringute ajal ka rauda, et ennetada rauavaegust (raua vähest sisaldust veres).
English: It is available in vials and in pre-filled syringes at various strengths ranging from 50 to 1,000 micrograms per millilitre.
Estonian: Seda turustatakse viaalides ja eeltäidetud süstaldes tugevusega 50-1000 μg/ml.
English: For more information about treatment with Mircera, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Mirceraga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Two of these studies involved patients who were starting treatment for anaemia.
Estonian: Neist kahes uuringus osalesid patsiendid, kellel alustati aneemia ravi.
English: This document is a summary of the European public assessment report (EPAR) for Mircera.
Estonian: See on ravimi Mircera Euroopa avaliku hindamisaruande kokkuvõte.
English: The other four studies (in 1,894 patients) were carried out in patients on dialysis who had already been receiving medicines to stimulate red blood cell production.
Estonian: Neli ülejäänud uuringut (1894 patsienti) tehti dialüüsi saavate patsientidega, kes juba said vere punalibleloome stimuleerimise ravimeid.
English: Mircera has been studied in six main studies involving a total of 2,399 adults with anaemia associated with chronic kidney disease.
Estonian: Mircerat uuriti kuues põhiuuringus, milles osales kokku 2399 kroonilise neeruhaigusega seotud aneemiaga täiskasvanud patsienti.
English: Similar response rates were seen in the patients taking the comparator medicines.
Estonian: Samasuguseid ravivastuseid täheldati ka võrdlusravimeid võtnud patsientidel.
English: In these studies, patients either remained on the medicines they were already receiving, or changed to Mircera, injected into a vein or under the skin every two or four weeks.
Estonian: Neis uuringutes kas jätkati ravi ravimitega, mida patsiendid juba võtsid, või asendati need Mirceraga, mida süstiti veeni või subkutaanselt iga kahe või nelja nädala järel.
English: In the studies of patients who had already been receiving medicines to stimulate red blood cell production, patients who changed to Mircera maintained their haemoglobin levels as effectively as the patients who remained on their existing medicines.
Estonian: Uuringutes patsientidega, kes juba said vere punalibleloome stimuleerimise ravimeid, säilitasid Mircera kasutamisele üle läinud patsiendid hemoglobiini sisalduse sama efektiivselt kui patsiendid, kes jätkasid olemasolevate ravimite võtmist.
English: In all six studies, the main measure of effectiveness was the change in haemoglobin levels.
Estonian: Efektiivsuse põhinäitaja kõigis kuues uuringus oli hemoglobiini sisalduse muutus.
English: In patients with chronic kidney disease, the main cause of their anaemia is a lack of natural erythropoietin.
Estonian: Pikaajalise neerupuudulikkusega patsientidel on aneemia peamine põhjus loodusliku erütropoetiini puudumine.
English: Other information about Mircera:
Estonian: Muu teave Mircera kohta
English: In the studies of patients starting treatment for anaemia for the first time, 126 (93%) of the 135 patients on dialysis, and 158 (98%) of the 162 not on dialysis had a significant increase in haemoglobin levels with Mircera.
Estonian: Uuringutes patsientidega, kellel alustati aneemiaravi esmakordselt, tõusis Mircerat saanud patsientidel hemoglobiini sisaldus uuringu lõpuks olulisel määral: dialüüsi saavatest patsientidest 93%-l (126 patsienti 135st) ja dialüüsi mittesaavatest patsientidest 98%-l (158 patsienti 162st) .
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Mircera.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: The dose and the frequency of dosing depend on whether or not Mircera is replacing another medicine used to stimulate the production of red blood cells.
Estonian: Ravimi annus ja manustamissagedus sõltuvad sellest, kas Mirceraga asendatakse teist ravimit, mida kasutati vere punaliblede tekke stimuleerimiseks.
English: For the full list of all side effects reported with Mircera, see the package leaflet.
Estonian: Mircera kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Doses should be adjusted according to the patient's response, to obtain haemoglobin levels within the recommended range (between 10 and 12 grams per decilitre).
Estonian: Annust tuleb kohandada vastavalt patsiendi ravivastusele, et saavutada hemoglobiini soovituslik sisaldus (10-12 g/dl).
English: There was no overall change in haemoglobin levels over the course of these studies with any of the treatments.
Estonian: Nende uuringute kestel ei täheldatud ühegi raviviisi korral hemoglobiini sisalduse üldist muutust.
English: The second study showed that patients taking Mircera and those taking darbepoetin alfa had similar increases in haemoglobin levels (around 2 g/dl).
Estonian: Teine uuring näitas, et Mircerat või alfadarbepoetiini saanud patsientidel suurenes hemoglobiini sisaldus sarnasel määral (ligikaudu 2 g/dl).
English: It must also not be used in patients who have high blood pressure that is not controlled.
Estonian: Ravimit ei tohi kasutada ka patsiendid, kelle hüpertensiooni ei ravita.
English: The epoetin beta is produced by ‘recombinant DNA technology': it is made by a cell that has received a gene, which makes it able to produce epoetin beta.
Estonian: Beetaepoetiini valmistatakse rekombinant-DNA-tehnika abil: seda toodab rakk, millele on lisatud beetaepoetiini teket võimaldav geen.
English: What is the risk associated with Mircera?
Estonian: Mis riskid Mirceraga kaasnevad?
English: Mircera was compared with other medicines used to stimulate red blood cell production.
Estonian: Mircerat võrreldi teiste ravimitega, mida kasutatakse vere punalibleloome stimuleerimiseks.
English: Why has Mircera been approved?
Estonian: Miks Mircera heaks kiideti?
English: What is Mircera?
Estonian: Mis on Mircera?
English: The CHMP concluded that Mircera corrected and maintained haemoglobin levels in patients with chronic kidney disease and that its effects are comparable with those of other epoetins.
Estonian: Inimravimite komitee järeldas, et Mircera korrigeeris ja säilitas kroonilise neeruhaigusega patsientide hemoglobiini sisaldust ning ravimi toime on võrreldav muude epoetiinide toimega.
English: The first study, in 181 patients on dialysis (a blood clearance technique used in advanced kidney disease), looked at Mircera injected into a vein every two weeks over 24 weeks and compared it with epoetin alfa or beta.
Estonian: Esimeses uuringus (181 patsienti, kellele tehti dialüüsi - kaugelearenenud neeruhaiguse korral kasutatav verepuhastusmeetod) võrreldi 24 nädala jooksul iga 2 nädala tagant veeni süstitava Mircera toimet alfaepoetiini või beetaepoetiini toimega.
English: Haemoglobin is the protein in red blood cells that carries oxygen around the body.
Estonian: Hemoglobiin on vere punalibledes sisalduv valk, mis kannab hapnikku organismis laiali.
English: Mircera must not be used in people who are hypersensitive (allergic) to methoxy polyethylene glycolepoetin beta or any of the other ingredients.
Estonian: Mircerat ei tohi kasutada patsiendid, kes on metoksüpolüetüleenglükool-beetaepoetiini või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: Treatment with Mircera must be started under the supervision of a doctor who has experience in the management of patients with kidney disease.
Estonian: Ravi Mirceraga peab alustama neeruhaigusega patsientide ravis kogenud arsti järelevalve all.
English: The second study, in 324 patients not on dialysis, looked at Mircera injected under the skin every two weeks over 28 weeks, comparing it with darbepoetin alfa.
Estonian: Teises uuringus (324 patsienti, kellele ei tehtud dialüüsi) võrreldi 28 nädala jooksul iga 2 nädala tagant subkutaanselt süstitava Mircera toimet alfadarbepoetiini toimega.
English: The active substance in Mircera, methoxy polyethylene glycol-epoetin beta, works like natural erythropoietin to stimulate red blood cell production, because it can attach itself to the same receptors as erythropoietin.
Estonian: Mirceras toimeainena sisalduv metoksüpolüetüleenglükool-beetaepoetiin stimuleerib vere punalibleloomet samal viisil kui looduslik erütropoetiin, sest see võib kinnituda samadele retseptoritele kui erütropoetiin.
English: Mircera methoxy polyethylene glycol-epoetin beta
Estonian: Mircera metoksüpolüetüleenglükool-beetaepoetiin
English: The active substance in Mircera is made up of epoetin beta attached to a chemical called methoxypolyethylene glycol.
Estonian: Mircera toimeaine koosneb beetaepoetiinist, mis on seondunud keemilise aine metoksüpolüetüleenglükooliga.
English: How is Mircera used?
Estonian: Kuidas Mircerat kasutatakse?
English: Mircera is a solution for injection that contains the active substance methoxy polyethylene glycolepoetin beta.
Estonian: Mircera on süstelahus, mis sisaldab toimeainena metoksüpolüetüleenglükool-beetaepoetiini.
English: What is Mircera used for?
Estonian: Milleks Mircerat kasutatakse?
English: What benefit has Mircera shown during the studies?
Estonian: Milles seisneb uuringute põhjal Mircera kasulikkus?
English: Mircera is used to treat anaemia (low red blood cell counts) that is causing symptoms in adults with chronic kidney disease (long-term, progressive decrease in the ability of the kidneys to work properly).
Estonian: Mircerat kasutatakse kroonilise neeruhaigusega kaasneva aneemia (punaliblede vähesus veres) raviks täiskasvanud patsientidel.
English: Mircera was as effective as the comparator medicines in correcting and maintaining haemoglobin levels.
Estonian: Mircera korrigeeris ja säilitas hemoglobiini sisaldust veres sama efektiivselt kui võrdlusravimid.
English: How has Mircera been studied?
Estonian: Kuidas Mircerat uuriti?
English: Invasive procedure was performed between Days 9 and 14.
Estonian: Invasiivne protseduur tehti 9. kuni 14. päeval.
English: Your treatment will start at least 8 days before your surgery or procedure.
Estonian: Teie ravi algab vähemalt 8 päeva enne teie operatsiooni või protseduuri.
English: If you forget to take a tablet
Estonian: Kui te unustate tabletti võtta
English: If possible, show them the pack, or this leaflet.
Estonian: Kui võimalik, näidake neile pakendit või seda infolehte.
English: Mulpleo should not be taken for more than 7 days.
Estonian: Mulpleot ei tohi võtta rohkem kui 7 päeva.
English: It can be taken with or without food.
Estonian: Seda võib võtta koos toiduga või ilma.
English: The effect of Mulpleo during pregnancy is not known.
Estonian: Mulpleo mõju raseduse ajal ei ole teada.
English: Therefore, a risk to the breast-feeding child cannot be excluded.
Estonian: Seega ei saa riski rinnaga toidetavatele imikutele välistada.
English: If you take more than you should
Estonian: Kui te võtate rohkem kui ette nähtud
English: Patients with body weight <45 Kg
Estonian: Patsiendid kehakaaluga < 45 kg
English: Total - n - Median (days) - (Q1, Q3) - P value [a]
Estonian: Kokku - n - Mediaan (päevades) - (Q1, Q3) - P-väärtus [a]
English: Human plasma protein binding ratio is ≥ 99.9%.
Estonian: Seondumine inimese plasmavalkudega on ≥ 99,9%.
English: - Tell your doctor if you are pregnant, think you may be pregnant, or are planning to have a baby.
Estonian: - Öelge oma arstile, kui te olete rase või arvate end olevat rase või kavatsete rasestuda.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/18/1348
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/18/1348
English: Pre- and post-natal development
Estonian: Pre- ja postnataalne areng
English: Recommended dose: take one tablet once a day, at the same time each day, for seven days only.
Estonian: Soovitatav annus: võtke üks tablett üks kord ööpäevas iga päev samal ajal, ainult seitsme päeva jooksul.
English: Do not give this medicine to children or adolescents under the age of 18 years, because the medicine has not been studied in children and adolescents.
Estonian: Ärge andke seda ravimit alla 18 aasta vanustele lastele ega noorukitele, sest selle ravimi kasutamist lastel ja noorukitel ei ole uuritud.
English: You can take it with food or between meals.
Estonian: Seda võib võtta koos toiduga või söögikordade vahel.
English: Other medicines and Mulpleo Tell your doctor if you are taking, have recently taken or might take any other medicines.
Estonian: Muud ravimid ja Mulpleo Teatage oma arstile, kui te võtate või olete hiljuti võtnud või kavatsete võtta mis tahes muid ravimeid.
English: Lusutrombopag 3 mg
Estonian: Lusutrombopaag 3 mg
English: If you miss a tablet of Mulpleo, take it as soon as you remember on the same day.
Estonian: Kui olete Mulpleo tableti vahele jätnud, võtke see samal päeval kohe, kui teile meenub.
English: Kingsfordweg 151, 1043GR Amsterdam The Netherlands
Estonian: Kingsfordweg 151, 1043GR Amsterdam Holland
English: The p value and confidence interval were calculated using the Wald method.
Estonian: P-väärtust ja usaldusvahemikku arvutati Waldi meetodil.
English: Table 1 Adverse reactions System Organ Class
Estonian: Tabel 1 Kõrvaltoimed Organsüsteemi klass
English: What you need to know before you take Mulpleo
Estonian: Mida on vaja teada enne Mulpleo võtmist
English: Platelets are blood components that help the blood to clot and so prevent bleeding.
Estonian: Trombotsüüdid on vere komponendid, mis aitavad verel hüübida ja sellega verejookse ennetada.
English: Common side effects (may affect up to 1 in 10 people)
Estonian: Sagedad kõrvaltoimed (võib esineda kuni 1 inimesel 10st)
English: Mulpleo is used to reduce the risk of bleeding during surgery and other procedures (including tooth extractions and endoscopy).
Estonian: Mulpleot kasutatakse verejooksuriski vähendamiseks operatsiooni ja muude protseduuride ajal (kaasa arvatud hammaste väljatõmbamine ja endoskoopia).
English: Do not take Mulpleo: - if you are allergic to lusutrombopag or any of the other ingredients of this medicine (listed in section 6 under ‘What Mulpleo contains').
Estonian: Ärge võtke Mulpleot: - kui olete lusutrombopaagi või selle ravimi mis tahes teiste koostisosade (loetletud lõigus 6 „Mida Mulpleo sisaldab“) suhtes allergiline.
English: Platelet counts should be measured frequently and the condition of patients should be observed closely.
Estonian: Trombotsüütide arvu tuleb sageli mõõta ning tuleb hoolikalt jälgida patsiendi seisundit.
English: Co-administration with interferon preparations
Estonian: Manustamine koos interferooni preparaatidega
English: All 3 received 7 days of treatment with lusutrombopag.
Estonian: Kõik kolm said 7 päeva ravi lusutrombopaagiga.
English: - Use reliable methods of contraception while you are taking Mulpleo.
Estonian: - Kasutage Mulpleo võtmise ajal usaldusväärseid rasestumisvastaseid vahendeid.
English: INFORMATION IN BRAILLE Mulpleo
Estonian: TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) Mulpleo
English: Certain people may have a higher risk of blood clots, including people with liver disease, and medicines like Mulpleo could make this problem worse.
Estonian: Mõnel inimesel võib olla verehüüvete tekkimise risk suurenenud, sealhulgas kroonilise maksahaigusega inimestel, ning ravimid nagu Mulpleo võivad seda probleemi süvendada.
English: What Mulpleo looks like and contents of the pack
Estonian: Kuidas Mulpleo välja näeb ja pakendi sisu
English: The medicine helps to increase the number of platelets in your blood.
Estonian: See ravim aitab suurendada trombotsüütide arvu teie veres.
English: Mulpleo is for oral use.
Estonian: Mulpleo on suukaudseks kasutamiseks.
English: The procedure should be performed from day 9 after the start of lusutrombopag treatment.
Estonian: Protseduur tuleb teha alates 9. päevast pärast ravi alustamist lusutrombopaagiga.
English: Environmental risk assessment studies have shown that lusutrombopag has the potential to be very persistent, very bioaccumulative and toxic to the environment.
Estonian: Keskkonnariski hindamise uuringud on näidanud, et lusutrombopaag on potentsiaalselt väga püsiv, väga bioakumuleeruv ja mürgine keskkonnale.
English: The safety and efficacy of lusutrombopag in children and adolescents (< 18 years of age) have not been established.
Estonian: Lusutrombopaagi ohutus ja efektiivsus lastel ja noorukitel (vanuses alla 18 aasta) ei ole tõestatud.
English: The film-coated tablet is to be taken once daily with liquid, swallowed whole and should not be chewed, divided, or crushed.
Estonian: Õhukese polümeerikattega tabletti tuleb võtta üks kord ööpäevas koos vedelikuga, see tuleb tervelt alla neelata ja seda ei tohi närida, osadeks jagada ega purustada.
English: Do not stop taking Mulpleo without talking to your doctor and do not take Mulpleo for more than 7 days.
Estonian: Kui te lõpetate Mulpleo võtmise Ärge lõpetage Mulpleo võtmist arstiga nõu pidamata ning ärge võtke seda kauem kui 7 päeva.
English: Signs of a blood clot: look out for any of the signs below:
Estonian: Verehüübe nähud: jälgige end ükskõik millise alltoodud tunnuse suhtes:
English: Take the tablet with a liquid and swallow it whole.
Estonian: Võtke tablett koos vedelikuga ja neelake see tervelt alla.
English: What Mulpleo is and what it is used for What you need to know before you take Mulpleo How to take Mulpleo
Estonian: Mis ravim on Mulpleo ja milleks seda kasutatakse Mida on vaja teada enne Mulpleo võtmist Kuidas Mulpleot võtta
English: LUSU = lusutrombopag; Q1 = 25th percentile; Q3 = 75th percentile [a] P-value was calculated by the van Elteren test with platelet transfusion status as stratum.
Estonian: LUSU = lusutrombopaag; Q1 = 25. protsentiil; Q3 = 75. protsentiil [a] P-väärtus arvutati van Eltereni testina, kasutades kihina trombotsüütide ülekande staatust.
English: What Mulpleo is and what it is used for
Estonian: Mis ravim on Mulpleo ja milleks seda kasutatakse
English: This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodiumfree'.
Estonian: See ravim sisaldab vähem kui 1 mmol (23 mg) naatriumi ühes tabletis, see tähendab põhimõtteliselt naatriumivaba.
English: • sudden shortness of breath, especially with sharp pain in the chest or rapid breathing
Estonian: • äkki tekkiv õhupuudus, eriti terava valuga rinnus või hingamise kiirenemisega;
English: You may be monitored for side effects associated with excessive platelets such as blood clots (see section 2, ‘Warnings and precautions', and section 4, ‘Possible side effects').
Estonian: Teid võidakse jälgida trombotsüütide ülemäärase arvuga seotud kõrvaltoimete, näiteks verehüüvete suhtes (vt lõik 2 „Hoiatused ja ettevaatusabinõud” ja lõik 4 „Võimalikud kõrvaltoimed”).
English: Pharmacotherapeutic group: Antihemorrhagics, other systemic hemostatics, ATC code: B02BX07
Estonian: Farmakoterapeutiline rühm: verejooksu tõkestavad ained, teised süsteemsed hemostaatilised ained, ATC-kood: B02BX07
English: No dosage adjustment is expected for these patients.
Estonian: Annuse kohandamist neil patsientidel ei eeldata.
English: Eight lusutrombopag-treated subjects and 2 placebo-treated subjects received less than 7 days of treatment as they met the criterion for a responder prior to Day 7.
Estonian: 8 lusutrombopaagiga ravitud uuringus osalejat ja 2 platseeboga ravitud uuringus osalejat said ravi vähem kui 7 päeva, sest nad vastasid enne 7. päeva ravivastuse kriteeriumile.
English: Lusutrombopag is rarely excreted into urine (approximately 1%).
Estonian: Lusutrombopaag eritub harva uriiniga (ligikaudu 1%).